ArticlePloS one2025
Understanding the social dimensions of kidney care pathways: A scoping review protocol.
Article in PloS one, 2025. The graph could read no effect estimate from its abstract, so it casts no vote on the map. Cited by 1 paper.
What it found
Each row is one number read from the abstract, on the scale the paper reported it, with its interval. Left of the dashed line favours the treatment, right favours the comparator. Under each row is the sentence it came from. New to these charts? A ten-minute tutorial.
The abstract states no effect estimate the extractor could read, or names no intervention and outcome on the map, so this paper lights no cell and moves no belief. It is still indexed, cited and linked below.
The trial behind it
Trials whose registry record cites this paper, or whose number appears in the abstract. A trial that started after this paper was published is citing it as background, not reporting it.
Neither the registry nor the abstract names a trial number. If this is a trial report, that itself is worth knowing.
Who cites it
1 citing paper in PubMed.
Corrections and comments
PubMed lists nothing against this paper. Absence here is not a guarantee, only a check that was made.
Authors and funding
7 authors.
Funding
No grant is acknowledged in the PubMed record.
Abstract
objectiveThis scoping review aims to map the social dimensions of kidney care pathways.
introductionEnd-stage kidney disease places significant demands on patients, caregivers, healthcare professionals, and the broader healthcare system. Kidney replacement therapy and conservative kidney management are the common management pathways for end stage kidney disease, but its delivery entails substantial time, financial, and social costs. Research has documented some social aspects of kidney care pathways, but findings are fragmented across disciplines and have not been synthesised coherently. A scoping review is therefore needed to map the existing evidence, identify key domains of social impact, and highlight gaps to inform future research and policy.
methodEligible studies will include primary research that reports on the social dimensions of managing end-stage kidney disease (ESKD) in adults. Studies from all settings, involving relevant stakeholder groups including patients with end stage kidney disease, informal caregivers, healthcare staff, and Industrial and supply chain workers engaged in different roles associated with kidney replacement therapy and/or conservative kidney management, will be included. The review will follow JBI methodology. Peer-reviewed and grey literature will be identified through searches of electronic databases (MEDLINE, CINAHL, PsycInfo, SocINDEX, EconLit, Web of Science) and grey literature sources (including Google Scholar and organisational reports). Reference lists of relevant reviews and identified articles will also be screened to identify any other relevant articles. Two reviewers will independently screen records and extract data using a predefined form. Results will be synthesised narratively and presented in thematic and tabular formats. DISCUSSION: This scoping review aims to generate evidence on the social impact of kidney replacement therapy and conservative management across multiple stakeholder groups. The review will provide a structured overview of how social outcomes are conceptualised, measured, and reported across the kidney care continuum. REVIEW REGISTRATION: Open Science Framework osf.io/63wpk.
Indexed as
Identifiers
What OpenQuestion holds
Registered trials
Read under generation 80e0d062 · epoch 390. Bibliography from PubMed, PubMed Central and OpenAlex; grants from NIH RePORTER; trial links from ClinicalTrials.gov; estimates, votes and beliefs from the OpenQuestion graph.